SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...

Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK). We have previously reported that activation of a ...

Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in certain ...

*Patients with at least 6 months follow-up. ‡ Response rate in patients without a CHR at baseline. CCyR = Complete cytogenetic response; CHR = Complete hematologic response; MCyR = Major cytogenetic ...

In 1972, Janet Rowley sat at her dining room table and cut tiny chromosomes from photographs she had taken in her laboratory. One by one, she snipped out the small figures her children teasingly ...

Chronic myeloid leukemia (CML) is a rare blood cancer that develops in the bone marrow. Karyotyping is a genetic technique doctors use to diagnose CML and choose more effective treatments. Karyotyping ...

Cancer isn’t one disease. Each person's cancer has its own genetic signature that makes it unique. Your doctor can analyze your cancer's genes to predict how it will behave, how quickly it will grow, ...

The European Commission approved the drug, asciminib, for patients with advanced cases of chronic myeloid leukemia, Novartis said on Monday. The drug will be marketed under the name Scemblix, the same ...